Alector has been granted a patent for Siglec-9 ECD fusion molecules for treatment methods. The isolated fusion polypeptide includes a specific amino acid sequence and an Fc domain. GlobalData’s report on Alector gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Alector, Personalized cancer vaccines was a key innovation area identified from patents. Alector's grant share as of May 2024 was 16%. Grant share is based on the ratio of number of grants to total number of patents.
Patent granted for siglec-9 ecd fusion molecules
A recently granted patent (Publication Number: US11987612B2) discloses an isolated fusion polypeptide that includes a Siglec-9 extracellular domain (ECD) joined to an Fc domain. The Siglec-9 ECD has a specific amino acid sequence and lacks another specific sequence, while the Fc domain can have a human IgG1 or IgG4 isotype. The Fc domain with a human IgG1 isotype has reduced binding to Fc?RIII, reduced antibody-dependent cellular cytotoxicity (ADCC), and/or increased binding to Fc?RIIa, among other characteristics.
Furthermore, the patent describes the isolated polypeptide's ability to bind sialic acid on cell surfaces, particularly tumor cells, myeloid cells, and myeloid-derived suppressor cells (MDSCs). The polypeptide can block cell binding of various Siglec family members, relieve MDSC-mediated suppression of T-cells, repolarize MDSCs to a pro-inflammatory phenotype, and induce the expression of specific chemokines in MDSCs. Additionally, the polypeptide can reduce myeloid cell recruitment into the tumor microenvironment and bind to MDSCs with varying affinities. The patent also covers an isolated nucleic acid encoding the polypeptide, an expression vector, a host cell for production, a method of producing the polypeptide, and a pharmaceutical composition containing the polypeptide and a pharmaceutically acceptable carrier.
To know more about GlobalData’s detailed insights on Alector, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
